Restenosis: the cost to society

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Health Economics

Background:

• Restenosis affects 20-55% of arteries after percutaneous intervention, causing recurrent angina.
• Over half of patients with restenosis need revascularization within 6 months, and 80% within 6 years.
• Restenosis significantly increases healthcare costs due to repeat procedures and hospitalizations.

Purpose of the Study:

• To evaluate the economic impact of reducing restenosis rates.
• To analyze cost savings associated with interventions that decrease restenosis.
• To emphasize the importance of economic analysis in evaluating new therapies.

Main Methods:

• Economic analysis of clinical trial data (EPIC trial).
• Calculation of potential cost savings based on risk reduction percentages.
• Comparison of cost-effectiveness of different interventions like c7E3 and stent implantation.

Main Results:

• A 26% reduction in restenosis with c7E3 treatment saved over $1000 per patient in medical costs.
• Reducing restenosis risk by 25% could save $1400 per patient; a 33% reduction could save $2000 per patient.
• Stent implantation also demonstrated potential for significant cost savings.

Conclusions:

• Interventions that reduce restenosis offer substantial economic benefits.
• Prospective cost analysis is crucial for evaluating the value of new medical therapies.
• Minimizing restenosis through effective treatments like c7E3 or stenting improves patient outcomes and reduces healthcare burden.